SEARCH RESULTS FOR: "Tag: HALO"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2018(3)
2017(4)
2015(11)
2014(1)
CATEGORIES
Analyst Downgrades(1)
Analyst Update(4)
Analyst Upgrades(1)
Buzz Stocks(2)
By the Numbers(1)
Expectational Analysis(1)
General(4)
Intraday Option Activity(1)
Opening View(1)
Stock Market News(1)
Stocks On the Move(2)
The Week Ahead(1)

5/11/2018 10:03 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is down 9.3% to trade at $18.12 this morning, after the biotech company reported first-quarter revenue short of analysts' forecasts, as well as a weaker...
2/21/2018 10:30 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is up 3.1% to trade at $19.11 this morning, after Canaccord Genuity upped its price target on the oncology specialist to $21 from $19. The analyst in co...
1/17/2018 9:27 AM
Shares of oncology biotech Halozyme Therapeutics, Inc. (NASDAQ:HALO) are trading 12.2% lower before the open, after Deutsche Bank analyst Andrew Peters cut his price target by $2 to $19. Peters label...
11/8/2017 9:34 AM
Analysts are weighing in on Grand Theft Auto parent Take-Two Interactive Software, Inc. (NASDAQ:TTWO), biotech Halozyme Therapeutics, Inc. (NASDAQ:HALO), and photonics stock Coherent, Inc. (NASDAQ:C...
9/14/2017 9:19 AM
Dow Jones Industrial Average (DJIA) futures are pointed slightly lower this morning, after notching a record-high close and fourth straight win yesterday. Futures on the S&P 500 Index (SPX) and N...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center